Reven Pharmaceuticals, Inc.

United States of America

Back to Profile
1-8 of 8 for Reven Pharmaceuticals, Inc. Sort by
Query
Aggregations
Jurisdiction
        United States 6
        World 2
Date
2025 August 1
2025 (YTD) 1
2022 1
Before 2020 6
IPC Class
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof 7
A61K 31/4415 - Pyridoxine, i.e.vitamin B6 6
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides 6
A61K 31/51 - Thiamines, e.g. vitamin B1 6
A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2 6
See more
Status
Pending 1
Registered / In Force 7
Found results for  patents

1.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF INFLAMMATION

      
Application Number 18029529
Status Pending
Filing Date 2021-09-30
First Publication Date 2025-08-28
Owner REVEN PHARMACEUTICALS INC. (USA)
Inventor
  • Uckun, Fatih M.
  • Volk, Michael A.
  • Lange, Peter
  • Denomme, Brian D.
  • Van Wyk, Hendrick Johanness Petrus

Abstract

The disclosure relates to pharmaceutical compositions and methods for the prevention and/or treatment of inflammation, disease, and disorders. The treatment may include treatment of COVID-19.

IPC Classes  ?

  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
  • A61P 31/14 - Antivirals for RNA viruses

2.

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF INFLAMMATION

      
Application Number US2021052884
Publication Number 2022/072637
Status In Force
Filing Date 2021-09-30
Publication Date 2022-04-07
Owner REVEN PHARMACEUTICALS INC. (USA)
Inventor
  • Uckun, Fatih M.
  • Volk, Michael A.
  • Lange, Peter
  • Denomme, Brian D.
  • Van Wyk, Hendrick Johanness Petrus

Abstract

The disclosure relates to pharmaceutical compositions and methods for the prevention and/or treatment of inflammation, disease, and disorders. The treatment may include treatment of COVID-19.

IPC Classes  ?

3.

Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution

      
Application Number 15848853
Grant Number 11202798
Status In Force
Filing Date 2017-12-20
First Publication Date 2018-08-30
Grant Date 2021-12-21
Owner REVEN PHARMACEUTICALS, INC. (USA)
Inventor
  • Lange, Peter
  • Denomme, Brian
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Tracy L.
  • Ozgur, Sezgin
  • Haroon, Zishan

Abstract

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

IPC Classes  ?

  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 33/10 - CarbonatesBicarbonates
  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A23L 33/15 - Vitamins
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
  • A61K 47/02 - Inorganic compounds
  • A61K 47/40 - CyclodextrinsDerivatives thereof
  • A61K 33/40 - Peroxides
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 33/20 - Elemental chlorineInorganic compounds releasing chlorine
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/20 - HalogensCompounds thereof
  • A61K 8/41 - Amines
  • A61K 8/42 - Amides
  • A61K 8/67 - Vitamins
  • A61K 8/73 - Polysaccharides
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/465 - NicotineDerivatives thereof
  • A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
  • A61K 31/65 - Tetracyclines
  • A61K 31/727 - HeparinHeparan
  • A61K 33/12 - Magnesium silicate
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61Q 19/00 - Preparations for care of the skin
  • A61Q 19/08 - Anti-ageing preparations

4.

Compositions and methods for the prevention and treatment of cardiovascular diseases

      
Application Number 15692694
Grant Number 11110053
Status In Force
Filing Date 2017-08-31
First Publication Date 2017-12-21
Grant Date 2021-09-07
Owner REVEN PHARMACEUTICALS INC. (USA)
Inventor
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Trace
  • Lange, Peter
  • Denomme, Brian
  • Volk, Michael A.

Abstract

Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
  • A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
  • A61K 31/16 - Amides, e.g. hydroxamic acids
  • A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
  • A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

5.

Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution

      
Application Number 15398233
Grant Number 09867849
Status In Force
Filing Date 2017-01-04
First Publication Date 2017-04-27
Grant Date 2018-01-16
Owner REVEN PHARMACEUTICALS, INC. (USA)
Inventor
  • Lange, Peter
  • Denomme, Brian
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Tracy L.
  • Ozgur, Sezgin
  • Haroon, Zishan

Abstract

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

IPC Classes  ?

  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
  • A61K 33/40 - Peroxides
  • A61K 47/02 - Inorganic compounds
  • A61K 47/40 - CyclodextrinsDerivatives thereof
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 33/20 - Elemental chlorineInorganic compounds releasing chlorine
  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A23L 33/15 - Vitamins
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/20 - HalogensCompounds thereof
  • A61K 8/41 - Amines
  • A61K 8/42 - Amides
  • A61K 8/67 - Vitamins
  • A61K 8/73 - Polysaccharides
  • A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
  • A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/465 - NicotineDerivatives thereof
  • A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
  • A61K 31/65 - Tetracyclines
  • A61K 31/727 - HeparinHeparan
  • A61K 33/12 - Magnesium silicate
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61Q 19/00 - Preparations for care of the skin
  • A61Q 19/08 - Anti-ageing preparations

6.

Compositions and methods for the prevention and treatment of cardiovascular diseases

      
Application Number 14550677
Grant Number 09775798
Status In Force
Filing Date 2014-11-21
First Publication Date 2015-05-21
Grant Date 2017-10-03
Owner REVEN PHARMACEUTICALS, INC. (USA)
Inventor
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Trace
  • Lange, Peter
  • Denomme, Brian
  • Volk, Michael A.

Abstract

Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
  • A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
  • A61K 31/16 - Amides, e.g. hydroxamic acids
  • A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
  • A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

7.

Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution

      
Application Number 14017811
Grant Number 09572810
Status In Force
Filing Date 2013-09-04
First Publication Date 2014-01-02
Grant Date 2017-02-21
Owner REVEN PHARMACEUTICALS, INC. (USA)
Inventor
  • Lange, Peter
  • Denomme, Brian
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Tracy L.
  • Ozgur, Sezgin
  • Haroon, Zishan

Abstract

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

IPC Classes  ?

  • A61K 31/51 - Thiamines, e.g. vitamin B1
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
  • A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
  • A61K 33/00 - Medicinal preparations containing inorganic active ingredients
  • A61K 33/40 - Peroxides
  • A61K 47/02 - Inorganic compounds
  • A61K 47/40 - CyclodextrinsDerivatives thereof
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
  • A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
  • A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
  • A61K 33/20 - Elemental chlorineInorganic compounds releasing chlorine

8.

METHODS OF TREATING OR AMELIORATING DISEASES AND ENHANCING PERFORMANCE COMPRISING THE USE OF A MAGNETIC DIPOLE STABILIZED SOLUTION

      
Application Number US2011044947
Publication Number 2012/012682
Status In Force
Filing Date 2011-07-22
Publication Date 2012-01-26
Owner REVEN PHARMACEUTICALS, INC. (USA)
Inventor
  • Haroon, Zishan
  • Lange, Peter
  • Denomme, Brian
  • Van Wyk, Henk
  • Van Wyk, Mariette
  • Krebs, Tracy L.
  • Ozgur, Sezgin

Abstract

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

IPC Classes  ?

  • A61K 33/24 - Heavy metalsCompounds thereof
  • A23L 2/00 - Non-alcoholic beveragesDry compositions or concentrates thereforPreparation or treatment thereof